Treatment interruptions can lead to the emergence of new resistances.
Problems of treatment interruption by the patient (e.g. discontinuation of certain drugs, recurrent treatment interruptions) should be detected and addressed (management of adverse events if necessary and reinforcement of patient support measures).
Interruption of the entire treatment for two consecutive months or more meet the definition of "lost to follow-up" (Chapter 17).
For management of patients who interrupt treatment, see Chapter 9.